LONG TERM OUTCOME OF αßTCR/CD19 DEPLETED HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULTS WITH ACUTE LEUKEMIA. A SINGLE CENTER EXPERIENCE. (EHA 2025) - May 16, 2025 - Abstract #PS2069; Pres time: Jun 14, 2025; 06:30 PM - 07:30 PM; Location: Poster Hall; "Conditioning regimen consisted in Treosulfan 30gr/m2 (TREO30) increased to 36 gr/m2 (TREO36) since 2017, associated to Thiotepa 10 mg/Kg and Fludarabine 150 mg/m2...No CMV reactivations or diseases were noted in post letermovir era, while before letermovir CMV reactivation occurred in 30% of analyzed population... These data represent the longest reported follow up of αβTCR/CD19-based depletion haploidentical HSCT in a cohort of adult acute leukemia. This study confirms that this platform is an effective option to achieve deep disease complete remission and improvement in term of overall survival and disease free survival in patients who lack a matched donor or need urgently an allograft, especially if in CR at time of transplant. Moreover the toxicity profile is very tolerable in heavily pretreated population even with higher doses of treosulfan in combination with another alkylant drug."
Clinical • Acute Graft versus Host Disease • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Hepatology • Immunology • Leukemia • Oncology • Pediatrics • Transplant Rejection • Transplantation
|
|
Lucia Prezioso; Amelia Rinaldi; Benedetta Cambo'; Sabrina Bonomini; Roberta Segreto; Luisa Craviotto; Gabriella Sammarelli; Giannalisa Todaro; Maurizio Soli; Silvia Giuliodori; Pamela Berni; Claudia Labate; Giovanni Roti
|